DSP Healthcare Fund Regular-Growth
The fund is rated 4 stars. The strongest areas were investment selection within each asset type and investment selection within each industry, while balance between returns and downside risk provided some support. Higher annual fee of 2.05% and above-average fund size of Rs 3,835.28 crore were minor drawbacks.
This fund has a good track record with Asset Selection/Timing, a good track record with Stock Selection/Timing. It is important to note, however, that this fund has a 3835.275 AUM and a 2.05 expense ratio. Considering all these factors, we have rated this fund as 4.0 star.
Our score weighs long-term performance, risk and consistency — not just past returns.
Returns
As of 7 Oct 2026
Risk ratios
As of 30 Sep 2026
Portfolio
As of 31 Aug 2026
Market-cap split
Sector allocation
Holdings (32)
| Holding | % of fund | Value | Shares |
|---|---|---|---|
| Ipca Laboratories Ltd. | 8.74% | ₹335.02 Cr | 16,96,381 |
| Sun Pharmaceutical Industries Ltd. | 7.95% | ₹304.78 Cr | 15,35,592 |
| Sai Life Sciences Ltd. | 7.45% | ₹285.72 Cr | 19,57,356 |
| Cipla Ltd. | 7.35% | ₹282.03 Cr | 20,01,379 |
| Apollo Hospitals Enterprise Ltd. | 6.47% | ₹248.03 Cr | 2,78,729 |
| Gland Pharma Ltd. | 5.98% | ₹229.5 Cr | 7,95,267 |
| Globus Medical Inc | 5.44% | ₹208.77 Cr | 2,68,800 |
| Divi's Laboratories Ltd. | 4.15% | ₹159.26 Cr | 1,68,223 |
| Alkem Laboratories Ltd. | 4.08% | ₹156.61 Cr | 2,93,861 |
| Cohance Lifesciences Ltd. | 3.81% | ₹146.04 Cr | 32,02,999 |
Fund details
Long term capital growth. Investment in equity and equity related Securities of healthcare and pharmaceutical companies/entities.
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies/entities.
Exit load of 0.50% if redeemed within 1 month.